ABSTRACT
The results of segidrin administration to 46 patients with malignant and 6 patients with benign tumors of the brain are presented. Pronounced therapeutic effect for the whole group was 63.5% and 73%, if partial regression of neurologic symptoms in the entire brain and separate foci is considered. These indexes for patients with malignant tumors only were 61 and 71.7%, respectively. Since segidrin has virtually no significant untoward side-effects, it is considered a most safe medicine for managing brain tumors. It is recommended in cases of inoperable tumor and for post-operative adjuvant chemotherapy with a view to extending the patient's survival time and improving the quality of life.
Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Hydrazines/therapeutic use , Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Treatment OutcomeABSTRACT
The paper discusses results of a cooperative study of effectiveness of hydrazine sulfate therapy in 740 patients with primary advanced, recurrent and metastatic solid tumors and malignant lymphomas who had failed all other treatment modalities. Both objective response and symptomatic effect were assessed. Objective response was observed in neuroblastoma, recurrent desmoid, Hodgkin's disease, lung cancer, fibrosarcoma and other tumors. Since hydrazine sulfate provided relief of a wide spectrum of cancer symptoms, it may be recommended for patients with end-stage cancer.
Subject(s)
Antineoplastic Agents/therapeutic use , Hydrazines/therapeutic use , Adolescent , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Drug Evaluation , Female , Humans , Hydrazines/administration & dosage , Hydrazines/adverse effects , Male , Middle Aged , Multicenter Studies as Topic , Neoplasm Recurrence, Local/drug therapy , Neoplasms/drug therapy , Remission Induction , Tablets, Enteric-Coated , Time FactorsABSTRACT
With a purpose of providing efficient treatment of extended lymphogranulomatosis resistant to the routine COPP program, new programs of polychemotherapy including the use of an antibiotic, plant alkaloid, alkylating agent and glucocorticoid were developed and studied. The optimal rhythm and regimen of the drug administration were developed. The study was based on the treatment of 65 patients. The clinical trials showed that the ALVP program including the use of adriablastin, lofenal, vinblastin and prednisolone was the most efficient. Its use provided a significant therapeutic effect in 77 per cent of the patients. The BrLVP program including the use of bruneomycin, lofenal, vinblastin and prednisolone, the RLVP program including the use of rubomycin, lofenal, vinblastin and prednisolone, the DLVP program including the use of dactinomycin, lofenal, vinblastin and prednisolone and the BlLVP program including the use of bleomycin, lofenal, vinblastin and prednisolone were less efficient and provided the therapeutic effect in 66, 63, 60 and 60 per cent of the patients respectively. The direction of shifts in the spectrum of the blood serum enzymes mainly corresponded to the results of clinical trials. This first of all referred to the ALVP and BrLVP programs. The use of these programs provided normalization of the hexokinase and lactate dehydrogenase activity of the serum and positive shifts in the isoenzyme spectrum.
